- Home
- IMVT vs APLS Comparison
IMVT vs APLS Comparison
Compare IMVT & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- APLS
- Stock Information
- Founded
- IMVT 2018
- APLS 2009
- Country
- IMVT United States
- APLS United States
- Employees
- IMVT N/A
- APLS N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- IMVT Health Care
- APLS Health Care
- Exchange
- IMVT Nasdaq
- APLS Nasdaq
- Market Cap
- IMVT 2.7B
- APLS 2.9B
- IPO Year
- IMVT N/A
- APLS 2017
- Fundamental
- Price
- IMVT $18.98
- APLS $27.31
- Analyst Decision
- IMVT Buy
- APLS Buy
- Analyst Count
- IMVT 9
- APLS 19
- Target Price
- IMVT $27.71
- APLS $33.63
- AVG Volume (30 Days)
- IMVT 1.7M
- APLS 2.1M
- Earning Date
- IMVT 11-06-2025
- APLS 10-30-2025
- Dividend Yield
- IMVT N/A
- APLS N/A
- EPS Growth
- IMVT N/A
- APLS N/A
- EPS
- IMVT N/A
- APLS N/A
- Revenue
- IMVT N/A
- APLS $754,649,000.00
- Revenue This Year
- IMVT N/A
- APLS $21.75
- Revenue Next Year
- IMVT N/A
- APLS N/A
- P/E Ratio
- IMVT N/A
- APLS N/A
- Revenue Growth
- IMVT N/A
- APLS 20.02
- 52 Week Low
- IMVT $12.72
- APLS $16.10
- 52 Week High
- IMVT $32.10
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- IMVT 68.97
- APLS 63.40
- Support Level
- IMVT $17.03
- APLS $23.85
- Resistance Level
- IMVT $18.34
- APLS $25.73
- Average True Range (ATR)
- IMVT 0.91
- APLS 1.19
- MACD
- IMVT 0.20
- APLS 0.30
- Stochastic Oscillator
- IMVT 93.99
- APLS 93.81
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.